PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277824
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in
      Non-small Cell Lung Cancer.
PG  - 559-563
AB  - AIM: To find new predictive factors for the efficient use of immune checkpoint
      inhibitors in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND
      METHODS: In this multicenter retrospective cohort study, we evaluated consecutive
      patients treated with nivolumab between January and October 2016 after
      second-line systemic chemotherapy. The endpoint was progression-free survival
      (PFS), as defined by Response Evaluation Criteria in Solid Tumors version 1.1.
      RESULTS: A total of 189 patients were included in the study. Sixty-four percent
      had received two or more prior systemic therapies. In Cox proportional hazard
      analyses, Eastern Cooperative Oncology Group Performance Status of 2 or more,
      lactate dehydrogenase (LDH) >/=217 mg/dl, and carcinoembryonic antigen >/=13.8
      ng/ml were independently associated with inferior PFS. LDH was not associated in 
      the sensitivity analysis. CONCLUSION: In patients with NSCLC treated with
      nivolumab, worse pretreatment performance status, and higher carcinoembryonic
      antigen were associated with inferior PFS.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kataoka, Yuki
AU  - Kataoka Y
AD  - Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical
      Center, Amagasaki, Japan [email protected]
FAU - Hirano, Katsuya
AU  - Hirano K
AD  - Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical
      Center, Amagasaki, Japan.
FAU - Narabayashi, Tomoko
AU  - Narabayashi T
AD  - Department of Internal Medicine, Japan Community Health Care Organization Osaka
      Hospital, Fukushima, Japan.
FAU - Hara, Satoshi
AU  - Hara S
AD  - Respiratory Division, Department of Internal Medicine, Itami City Hospital,
      Itami, Japan.
FAU - Fujimoto, Daichi
AU  - Fujimoto D
AD  - Department of Respiratory Medicine, Kobe City Medical Center General Hospital,
      Kobe, Japan.
FAU - Tanaka, Tae
AU  - Tanaka T
AD  - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
FAU - Ebi, Noriyuki
AU  - Ebi N
AD  - Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan.
FAU - Tomii, Keisuke
AU  - Tomii K
AD  - Department of Respiratory Medicine, Kobe City Medical Center General Hospital,
      Kobe, Japan.
FAU - Yoshioka, Hiroshige
AU  - Yoshioka H
AD  - Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata,
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - Nivolumab
OT  - carcinoembryonic antigen
OT  - immunotherapy
OT  - non-small cell lung cancer
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/24 00:00 [received]
PHST- 2017/11/09 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/559 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):559-563.